Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting

0 Comments 2 view(s)

– 14 abstracts include data for Taltz in genital psoriasis, baricitinib in atopic dermatitis and mirikizumab in plaque psoriasis –

INDIANAPOLIS, Feb. 14, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), baricitinib and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place Feb. 16-20, 2018, in San Diego, Calif.

The data include eight abstracts for Taltz, featuring two oral presentations highlighting patient-reported outcomes from a Phase 3 clinical trial evaluating Taltz for the treatment of moderate-to-severe genital psoriasis, as well as findings from the Corrona Psoriasis Registry on Taltz patient clinical characteristics and treatment history. Two abstracts evaluating the efficacy and safety of Taltz for the treatment of active psoriatic arthritis will also be presented.

Additionally, Lilly will present Phase 2 efficacy, safety and patient-reported outcomes data for mirikizumab in moderate-to-severe plaque psoriasis. Lilly will also present a late-breaker abstract on patient-reported outcomes data from a Phase 2 study evaluating baricitinib for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners in the development of baricitinib). One abstract from the Closer Together Survey, a survey where nearly 2,000 people with moderate-to-severe psoriasis from 17 countries cross Europe and Canada shared how psoriasis impacts their quality of life and their overall satisfaction with treatment, will also be presented. An additional three abstracts will detail results from studies investigating immune-mediated diseases.

“The data being presented at AAD demonstrates our commitment to developing treatment advancements to help patients with severe diseases such as psoriasis and atopic dermatitis find relief,” said Lotus Mallbris, M.D., vice president, immunology platform team leader, Lilly Bio-Medicines. “We are pleased to share data underscoring the potential of our immunology portfolio.”

Studies, as well as the times and locations of the data sessions, are highlighted below.

Taltz Data

Oral Presentations

Saturday, Feb. 17

  • Abstract #6061: 11:25–11:30 a.m. PST, ePoster Presentation Center 2
    • Ixekizumab Patient Clinical Characteristics and Treatment History in Routine Clinical Practice: Findings from the Corrona Psoriasis Registry
    • Presenter: Jashin J. Wu, M.D., Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA

Monday, Feb. 19

  • Abstract #5935: 10:41–10:49 a.m. PST, Room 1A
    • Ixekizumab Provides Greater Improvement Versus Placebo on the Impact of Genital Psoriasis on Sexual Activity for Patients with Moderate-to-Severe Genital Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial
    • Presenter: Jennifer Clay Cather, M.D., Modern Research Associates, Dallas, TX

Posters

  • Abstract #6037: Ixekizumab Provides Rapid and Greater Improvement of the Symptoms of Genital Psoriasis Compared to Placebo in a Randomized, Double-Blind, Phase 3b Clinical Trial
    • Lead author: Gil Yosipovitch, M.D., University of Miami, Miami, FL
  • Abstract #6041: Ixekizumab Improves Nail and Skin Lesions through 52 Weeks in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors
    • Lead author: Joseph F. Merola, M.D., Harvard Medical School and Brigham and Women’s Hospital, Boston, MA
  • Abstract #6062: Ixekizumab Patient Demographics and Self-Reported Burden in Routine Clinical Practice: Findings from the Corrona Psoriasis Registry
    • Lead author: Jashin J. Wu, M.D., Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA
  • Abstract #6581: Long-Term Efficacy and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis Sustained for 3 Years: Results of a Randomized, Controlled Phase 3 Study (UNCOVER-3)
    • Lead author: Craig Leonardi, M.D., St. Louis University School of Medicine, St. Louis, MO
  • Abstract #6587: Ixekizumab Reduces Disease Activity up to 52 Weeks in Active Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: An Assessment Using Minimal Disease Activity Scores
    • Lead author: Joseph F. Merola, M.D., Harvard Medical School and Brigham and Women’s Hospital, Boston, MA
  • Abstract #7534: Ixekizumab Provides Greater Cumulative Benefits Versus Ustekinumab over 24 Weeks for Patients with Moderate-to-Severe Psoriasis in a Randomized, Double-Blind Phase 3b Clinical Trial
    • Lead author: Andrew Blauvelt, M.D., M.B.A., Oregon Medical Research Center, Portland, OR

Baricitinib Data

Late-Breaker Presentation

Saturday, Feb. 17

  • Abstract F061: 1 p.m.3 p.m. PST, Ballroom 20A
    • Patient-Reported Outcomes from a Phase 2 Double-Blinded, Randomized, Multi-Center, Placebo-Controlled Study of Baricitinib in Adult Patients with Moderate-to-Severe Atopic Dermatitis
    • Presenter: Emma Guttman-Yassky, M.D., Ph.D., Icahn School of Medicine, Mount Sinai Medical Center, New York, NY

Mirikizumab Data

Poster

  • Abstract #6131: Efficacy, Safety and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Mirikizumab (LY3074828) in a Phase 2 Study
    • Lead author: Phoebe Rich, M.D., Oregon Dermatology & Research Center, Portland, OR

Additional Data

Posters

  • Abstract #6109: The Impact of Psoriasis on Quality of Life …

Full story available on Benzinga.com